Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Jun 08, 2021 2:17pm
116 Views
Post# 33348790

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Galleri

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:GallerictDNA (Grail) vs mRNA (Stagezero)

2 different approaches. Looks like mRNA is the better of the 2 approaches and probably explains why our numbers are much better than Grails.  Ours is more of an early detection where theres is just a confirmation of later stages.





https://www.semanticscholar.org/paper/Circulating-Tumor-Cells%2C-DNA%2C-and-mRNA%3A-Potential-Xu-Dorsey/d730b71bc04ef5f57c935ee18307ecac6a86199f



davewho wrote: galleri seems to be DNA based using circulating cell tumor DNA or ctDNA for short. So you must have a cancer tumor for it to work is the way I understand it.

Tumors lose pieces of DNA, but they’re hard to find in the blood. Of the cell-free DNA in the blood of someone with cancer, the circulating tumor DNA (ctDNA) might account for just 0.1%. Once extracted, that ctDNA can be analyzed—usually with next-generation sequencing (NGS)—for modifications, such as single-nucleotide variants, insertion-deletion mutations, and copy-number variations. Those changes in ctDNA carry information about the kind of cancer that created it. That’s what most advanced cancer-screening tests look for in blood samples.

Catching cancer extremely early | Science | AAAS (sciencemag.org)



<< Previous
Bullboard Posts
Next >>